Hybrid Vigor Volume 1 Issue 7

Dear Friends,
Welcome to the fourth week of Hybrid Vigor!
We provide our usual Monday recap of the Hillside Ugly 20, along with a bonus list—10 names that may be subject to relatively quick premium contraction, as measured by our Hillside Adjusted Risk Point (HARP) score.  
We also provide Jeffrey Alton’s review of earnings reports from low-HARP names and talk about several convertibles that look to be providing reasonably attractive entry points.
Along the way, we chat briefly about Herbalife convertibles and a role they might play in the Pershing Square drama.
Finally, Kent Bailey has some insights on Biomarin, one of the most fascinating repeat-offending biotech convertible issuers out there.
Volatility looks like it’s trying to come back. That means more trading opportunities. We hope you’ll find Hybrid Vigor to be a useful resource in markets quiet and active alike. Thanks again for all your support and feedback.

Click here to download the newsletter

Bill Feingold
Co-Founder and Managing Principal
Hillside Advisors LLC

SMID Cap Healthcare Convertibles : Conference Insights

The principals of Hillside Advisors have long been fans of biotech convertibles—it’s a match almost as good as what Mr. Reese came up with mixing chocolate and peanut butter.  Unlike most industries, biotech recognizes its need for a constant flow of capital-market lifeblood and acts accordingly. Biotech companies don’t hesitate to float new shares after good news catapults the stock.

Read More